Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

BACKGROUND: Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin‐converting enzyme (ACE)‐inhibitor therapy vary between individuals. Our objective was to integrate clinical and pharmacogenetic determinants in an ultimate c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Oemrawsingh, Rohit M., Akkerhuis, K. Martijn, Van Vark, Laura C., Redekop, W. Ken, Rudez, Goran, Remme, Willem J., Bertrand, Michel E., Fox, Kim M., Ferrari, Roberto, Danser, A.H. Jan, de Maat, Moniek, Simoons, Maarten L., Brugts, Jasper J., Boersma, Eric
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943245/
https://ncbi.nlm.nih.gov/pubmed/27021566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002688
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados